Soleno Therapeutics (SLNO) Other financing activities (2014 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Other financing activities of $52000.0 for Q1 2026, down 80.67% year-over-year from $269000.0 in Q1 2025, and down 94.55% quarter-over-quarter from $954000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Other financing activities (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Other financing activities for 10 consecutive years, with $52000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 80.67% year-over-year to $52000.0; the TTM figure through Mar 2026 stood at $17.0 million (up 981.85% YoY), while the FY2025 annual figure was $17.2 million, up 1207.14% from the prior year.
- Other financing activities retreated to $52000.0 in Q1 2026 per SLNO's latest filing, from $954000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $13.7 million in Q2 2025 and bottomed at -$1000.0 in Q4 2024.
- Historically, Other financing activities has averaged $2.3 million across 5 years, with a median of $437000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities tumbled 100.3% — and 2025, when it surged 95500.0%.
- Soleno Therapeutics' Other financing activities stood at $16000.0 in 2022, then soared by 2006.25% to $337000.0 in 2023, then slumped by 100.3% to -$1000.0 in 2024, then soared by 95500.0% to $954000.0 in 2025, then sank by 94.55% to $52000.0 in 2026.
- Business Quant data shows SLNO's Other financing activities at $52000.0 in Q1 2026, $954000.0 in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | 954,000.00 |
| Dec 31, 2025 | 954,000.00 |
| Sep 30, 2025 | 2.26 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 13.72 Mn |
| Jun 30, 2025 | 13.72 Mn |
| Mar 31, 2025 | 269,000.00 |
| Mar 31, 2025 | 269,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 765,000.00 |
| Sep 30, 2024 | 765,000.00 |
| Jun 30, 2024 | 537,000.00 |
| Jun 30, 2024 | 537,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 337,000.00 |
| Dec 31, 2023 | 337,000.00 |